Literature DB >> 4005678

Malignant hyperthermia: a possible new variant.

D S Lee, J P Adams, J E Zimmerman.   

Abstract

A young healthy male, who had three consecutive episodes of postoperative hyperthermia was anaesthetized with special precautions to prevent malignant hyperthermia. Despite neuroleptic anaesthesia and dantrolene pretreatment, the patient experienced post-anaesthetic hyperthermia. The patient's clinical picture was almost identical to the symptoms experienced by two of his maternal relatives. All three experienced nausea, vomiting, muscle cramps and high fever which occurred between five to seven hours after general anaesthesia. The serum potassium (K) and creatinine phosphokinase (CPK) levels determined during the hyperthermic episode and on the next day were not elevated. On the basis of the patient's family history, his clinical picture, and his laboratory data, we speculate that this patient might have a form of malignant hyperthermia or a possible new variant.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4005678     DOI: 10.1007/bf03015141

Source DB:  PubMed          Journal:  Can Anaesth Soc J        ISSN: 0008-2856


  9 in total

1.  Dantrolene dose response in awake man: implications for management of malignant hyperthermia.

Authors:  E H Flewellen; T E Nelson; W P Jones; J F Arens; D L Wagner
Journal:  Anesthesiology       Date:  1983-10       Impact factor: 7.892

Review 2.  Dantrolene.

Authors:  B A Britt
Journal:  Can Anaesth Soc J       Date:  1984-01

3.  Malignant hyperthermia after oral and intravenous pretreatment with dantrolene in a patient susceptible to malignant hyperthermia.

Authors:  G Ruhland; A J Hinkle
Journal:  Anesthesiology       Date:  1984-02       Impact factor: 7.892

4.  Malignant hyperthermia following preoperative oral administration of dantrolene.

Authors:  D C Fitzgibbons
Journal:  Anesthesiology       Date:  1981-01       Impact factor: 7.892

5.  A stressful situation.

Authors:  D W Wingard
Journal:  Anesth Analg       Date:  1980-05       Impact factor: 5.108

6.  Human malignant hyperthermia: awake episodes and correction by dantrolene.

Authors:  G A Gronert; R L Thompson; B M Onofrio
Journal:  Anesth Analg       Date:  1980-05       Impact factor: 5.108

7.  Postoperative malignant hyperthermia episodes in patients who received "safe" anaesthetics.

Authors:  R Grinberg; G Edelist; A Gordon
Journal:  Can Anaesth Soc J       Date:  1983-05

8.  Successful use of dantrolene sodium in human malignant hyperthermia syndrome: a case report.

Authors:  C M Friesen; J B Brodsky; M F Dillingham
Journal:  Can Anaesth Soc J       Date:  1979-07

Review 9.  Malignant hyperthermia.

Authors:  G A Gronert
Journal:  Anesthesiology       Date:  1980-11       Impact factor: 7.892

  9 in total
  1 in total

Review 1.  Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.

Authors:  A Ward; M O Chaffman; E M Sorkin
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.